ASAN FOUNDATION
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1989-06-23
- Employees
- 501
- Market Cap
- -
- Website
- https://ails.amc.seoul.kr
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- Drug: Lopinavir/ritonavirDrug: Hydroxychloroquine sulfate
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 65
- Registration Number
- NCT04307693
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Phase 2
Active, not recruiting
- Conditions
- Biliary Tract NeoplasmsCholangiocarcinomaGallbladder Cancer
- Interventions
- Drug: Durvalumab + Gem/CisDrug: Gem/Cis
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT04308174
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Evaluation of Prevalence and Clinical Impact of Atrial Fibrillation in Elderly Patients With Cryptogenic Stroke and High-Risk Patent Foramen Ovale
Recruiting
- Conditions
- High Risk Patent Foramen OvaleCryptogenic Stroke
- Interventions
- Procedure: Percutaneous device closure
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 300
- Registration Number
- NCT04285918
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Evaluation of Cavernous Sinus Invasion by Pituitary Adenoma Using Deep Learning Based Denoising MR
Not Applicable
Completed
- Conditions
- Cavernous Sinus Invasion by Pituitary Adenoma
- Interventions
- Diagnostic Test: MRI with deep learning based denoising
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 67
- Registration Number
- NCT04268251
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology
Not Applicable
- Conditions
- Solid Carcinoma
- Interventions
- Procedure: fecal microbiota transplantation
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT04264975
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Surveillance in Ulcerative Colitis: Narrow Band Image Versus Chromoendoscopy for High-risk Groups
Not Applicable
- Conditions
- DysplasiaUlcerative Colitis
- Interventions
- Diagnostic Test: chromoendoscopy with target biopsy; NBI with target biopsy
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 188
- Registration Number
- NCT04257084
Efficacy and Safety of Precut-EMR for Resecting of Colonic Polyp
Not Applicable
Withdrawn
- Conditions
- Colonic Polyps
- Interventions
- Procedure: Precut EMRProcedure: Conventional MER
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Asan Medical Center
- Registration Number
- NCT04253990
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of
Effect of Head Elevation on LMA Insertion
Not Applicable
Completed
- Conditions
- Urinary Bladder NeoplasmsLaryngeal Masks
- Interventions
- Procedure: Laryngeal mask airway insertion
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT04229862
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Ertugliflozin for Functional Mitral Regurgitation
Phase 3
Completed
- Conditions
- Left Ventricular Systolic DysfunctionMitral Valve Insufficiency
- Interventions
- Drug: PlaceboDrug: Ertugliflozin
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 128
- Registration Number
- NCT04231331
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Docetaxel, Oxaliplatin, S-1 and DurvalumabDrug: Durvalumab and Tremelimumab
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 68
- Registration Number
- NCT04221555
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath